Company intelligence / Profile preview

Magenta Therapeutics

Cambridge, Massachusetts, United Statesleadiq.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Magenta’s lead program, MGTA -117, a CD117-targeted antibody-drug conjugate for targeted conditioning prior to hematopoietic stem cell transplant or gene therapy, showed promising single-agent activity and tolerability in early clinical trials. The company also advanced MGTA -145 for improved stem cell mobilization into Phase 2 studies but did not reach commercialization before winding down operations.

Therapeutic areas: OncologyHematology
Modalities: Antibody-drug conjugateCell therapySmall molecule
Industry: Biotech

Partnerships

bluebird bio (stem cell mobilization)Beam Therapeutics (“base editing” gene therapies with targeted conditioning)National Marrow Donor Program / Be The Match BioTherapies

Beyond the preview

Go deeper on Magenta Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Magenta Therapeutics.

Explore the full profile